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Portal hypertension and development of hepatocellular
carcinoma: Factors inﬂuencing signiﬁcance in prognostic modelsq
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Bispebjerg Bakke 23, 2400 Copenhagen NV, DenmarkSee Article, pages 923–928In this issue of the Journal, Ripoll et al. report inter-
esting results about the prognostic association of the
hepatic venous pressure gradient (HVPG) with the risk
of developing hepatocellular carcinoma (HCC) in early
cirrhosis [1]. They have developed three diﬀerent Cox
proportional hazards models, all of which include
HVPG as the most signiﬁcant predictor of HCC.
Although these new interesting results are entirely valid
in the patients used for their derivation, they are to some
extent unexpected, since well recognised prognostic vari-
ables in cirrhosis like age, Child-Pugh score, MELD,
serum bilirubin and INR (prothrombin time) had no sig-
niﬁcant independent prognostic inﬂuence in the models.
Several factors may have inﬂuenced this particular
outcome.
Selection criteria. The study is retrospective and
based on data from a randomized controlled trial
designed to evaluate the eﬃcacy of the non selective
beta-blocker timodol in preventing gastroesophageal
varices [2]. Patients were followed until development of
varices or variceal bleeding, which was the primary end
point. The admission criteria included cirrhosis and por-
tal hypertension. HVPG should be at least 6 mm Hg.
Among the included patients the median HVPG was
11 mm Hg (range 6–25) and 63% had HVPG
P10 mm Hg [1]. However, patients with gastroesopha-0168-8278/$36.00  2009 European Association for the Study of the Liver.
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Patients with ascites requiring diuretics were also
excluded. Thus the patients, which were actually
included in the study, were rather special: they had por-
tal hypertension, but had neither gastroesophageal var-
ices nor ascites. Of the included 213 patients, 89%
belonged to Child-Pugh class A and none to class C.
The mean Child Pugh score was 5.4 (median 5, range
5–8), mean bilirubin was 1.16 mg/dl (median 0.9, range
0.2–5.9), mean albumin was 3.9 g/dl (median 4.0, range
2.1–5.4), mean INR (prothrombin time) was 1.34 (med-
ian 1.1, range 1–2) and mean creatinine was 0.9 mg/dl
(median 0.9, range 0.2–1.9) [1,2]. Thus the patients seem
to belong to a somewhat special group of cirrhosis with
quite divergent variables: relatively more structural
ﬁbrotic and vascular abnormality [3,4] leading to ele-
vated HVPG but relatively little decompensation or
metabolic abnormality with little eﬀect on liver and kid-
ney function. Thus in the included patients the usual
biochemical prognostic variables in cirrhosis did not
vary as much as HVPG, which was allowed an unre-
stricted degree of abnormality. This could relatively
favour HVPG in the analysis and explain to some degree
why this variable achieved its prognostic inﬂuence.
Variables analysed. The variables recorded and avail-
able for analysis vary between prognostic studies [5].
Most frequently the easily obtainable variables like
symptoms, signs and simple laboratory tests are
recorded. Therefore these have a greater chance of being
analysed and included in prognostic models than more
special invasive investigations like measurement ofPublished by Elsevier B.V. All rights reserved.
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ating the hazard of the patient. Therefore the demon-
stration of the paramount prognostic importance of
HVPG in the paper by Ripoll et al. [1] underlines the
great importance of the structural hepatic vascular
anomalies [3,4] in regard to prognosis. However, not
all variables recorded may be selected for analysis
and for potential inclusion into a prognostic model.
Serum creatinine has been reported to be a prognostic
variable in cirrhosis in many studies [5]. Although this
variable was recorded, it was not selected for analysis
[1], probably because of its limited variation in the
included patients (see above).
The endpoint. In the paper by Ripoll et al. [1] this was
the development of HCC according to histological con-
ﬁrmation, typical image suggested by two radiological
techniques or only in one imaging technique with an
alpha-fetoprotein (AFP) greater than 400 ng/ml.
Although HCC is associated with cirrhosis, develop-
ment of HCC cannot be expected to have the same prog-
nostic indicators as cirrhosis. A recent review shows that
in HCC prognostic indicators comprise both tumour-
and liver-related variables including the Child-Pugh
class [6]. The demonstrated association between HVPG
and the development of HCC by Ripoll et al. [1] is
interesting since the study was not primarily designed
to predict the development of HCC, and baseline
alpha-fetoprotein (AFP) was only recorded retrospec-
tively as a binary variable [1] after termination of the
original study [2].
Scoring of variables. In a prognostic model the scor-
ing of the included variables will markedly aﬀect their
inﬂuence in the model [7,8]. Normally quantitative vari-
ables should be kept as such and not dichotomized, since
this will lead to loss of information. However, for regres-
sion models like the Cox model the assumption of pro-
portional hazards or linearity must be fulﬁlled. This may
necessitate a particular scoring of the included variables.
For example variables like bilirubin, INR (prothrombin
time), AST, ALT and creatinine most often need to be
included as the logarithm of the value for the assump-
tion of proportional hazards to be fulﬁlled. In the study
by Ripoll et al. [1] bilirubin, AST, ALT and INR was
studied without logarithmic transformation, and report-
edly they could not ﬁnd model assumptions to be vio-
lated. However, this could be due to the relatively
small variation of these variables among the patients
(see above). Alpha-fetoprotein (AFP) did not achieve
signiﬁcance in the ﬁnal Cox model, possibly because it
could only be scored as a binary variable [1].
Variable selection method. To reduce overﬁtting, vari-
ables should normally be included in the analysis inaccordance with their a priori probability of prognostic
inﬂuence. Ripoll et al. [1] used the stepwise backward
elimination method [8] in their Cox regression analyses.
As demonstrated in their Table 3 [1] starting with diﬀer-
ent sets of variables led to three diﬀerent ﬁnal Cox mod-
els as might be expected [8]. In addition, the inﬂuence of
ﬁrst order interactions between HVPG and the other
variables was studied, but none were signiﬁcant. Thus
the analyses had an explorative element, and this may
have given rise to slight overﬁtting. However, the
authors consider their models only explicative and do
not think they should be used for prediction purposes
in new patients [1] before they have been veriﬁed in inde-
pendent patients.
In summary, Ripoll et al. have provided new interest-
ing results on the association between HVPG and devel-
opment of HCC [1]. However, given the retrospective
nature of the study, the rather special selection criteria
and some particulars in the analysis, it would be impor-
tant to validate the results in independent patients. If
veriﬁed in new patients the results would provide an
important lead, both with regard to the pathogenesis
[9] and the screening strategy for HCC [10].References
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